Who are VIP/ABVD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FLOT, CEV chemotherapy, TAC chemotherapy, chemotherapy of mFOLFOX6 or FOLFIRI, SOX Chemotherapy, Dose dense AC followed by T + trastuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vip-abvd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

VIP/ABVD — Competitive Intelligence Brief

VIP/ABVD (VIP/ABVD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy regimen. Area: Oncology.

phase 3 chemotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

VIP/ABVD (VIP/ABVD) — University Hospital, Grenoble. VIP/ABVD is a chemotherapy regimen used to treat Hodgkin lymphoma.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VIP/ABVD TARGET	VIP/ABVD	University Hospital, Grenoble	phase 3	chemotherapy regimen
FLOT	FLOT	European Organisation for Research and Treatment of Cancer - EORTC	marketed	Chemotherapy regimen (combination)
CEV chemotherapy	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen
TAC chemotherapy	TAC chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
Dose dense AC followed by T + trastuzumab	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy regimen class)

University Hospital, Grenoble · 2 drugs in this class
Canadian Cancer Trials Group · 1 drug in this class
Centre Georges Francois Leclerc · 1 drug in this class
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · 1 drug in this class
French Innovative Leukemia Organisation · 1 drug in this class
AIO-Studien-gGmbH · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
National Research Center for Hematology, Russia · 1 drug in this class
Ospedale Santa Croce-Carle Cuneo · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VIP/ABVD — Competitive Intelligence Brief. https://druglandscape.com/ci/vip-abvd. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab